secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvex, Inc. (MOVE)
CIK:        0001734750
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001213900-23-021242
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Movano Health Q4 2022 net loss $7.9M; progressing toward summer 2023 Evie Ring launch
--------------------------------------------------------------------------------

- Net loss of $7.9M ($0.24/sh) in Q4 2022 vs $6.3M ($0.19/sh) in Q4 2021; no revenue in either period.
- Cash and equivalents $10.8M at Dec 31, 2022; completed $7.5M public offering in Q1 2023.
- Evie Ring on track for summer 2023 launch; second beta program with global athletic apparel and medical device firms.
- Plan to file first 510(k) for heart rate and SpO2 clearance this spring after successful hypoxia trial (2% SpO2 margin of error).
- Issued 9 new U.S. patents (21 total) for non-invasive blood pressure and glucose monitoring; first clinical studies imminent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1734750/000121390023021242/0001213900-23-021242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1734750/000121390023021242/ea175393-8k_movanoinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-021242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer